ZENAS BIOPHARMA INC
ZBIONASDAQTrading Snapshot
- Day Range
- $30.76 β $31.81
- 52-Week Range
- $13.50 β $44.60
- Volume
- $2.42B
- Avg Volume
- $1.90B
- Shares Outstanding
- 63.1M
- Next Earnings
- Sep 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $3M
- P/E Ratio
- -3.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-7.64
- Dividend Yield
- 0.00%
Why Investors Own ZBIO
- βHigh-growth profile β revenue up +23.0% YoY with expanding US Equity exposure.
- βHealthy economics β 77% gross margin and 25% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ZENAS BIOPHARMA INC
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
